Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

NCT04650581 PHASE3 ACTIVE_NOT_RECRUITING Results posted

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).

Details

Lead sponsor	Canadian Cancer Trials Group
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	250
Start date	Wed Jan 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Cancer

Interventions

• Ipatasertib
• Fulvestrant
• Placebo

Countries

New Zealand, Canada, Australia